Cytokinetics, Incorporated (CYTK)
Nasdaq · Healthcare · Biotechnology
$62.70−4.42%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $8.7B
- 52-week range
- $54.30 – $88.31
- 52-week change
- +9.02%
- EPS (trailing)
- −$7.22
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $88.0M (+376.56%)
- Net income
- −$785M
- Operating margin
- −695.4%
- Diluted EPS
- −$6.54
- Free cash flow
- −$535M
From the company’s annual report on SEC EDGAR.
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Headquarters: South San Francisco, United States · 673 employees · cytokinetics.com